Chinese Cell Therapy Firm Oricell Raises $110M in Pre-IPO Round to Accelerate Solid Tumor and In Vivo CAR-T Development

4Month10Day, Oricell Therapeutics (Oricell) officially announced the cumulative completion1.1Billion US dollarsPre-IPORound of financing. This round of financing was jointly led by Vivo Capital, Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, and a globally leading healthcare fund, with participation from an international sovereign fund, Yizhuang Guotou, Luxin Venture Capital,NGS(Australian Aged Care Industry Fund), Licheng Investment, Ruifeng Capital and other well-known institutions followed up with investments.

The proceeds from this round of financing will be mainly used to accelerate the international strategic layout of Qrigincell Therapeutics, promote the global multi-center clinical development of its core pipeline, further consolidate its technical barriers in the cell therapy field, and expedite the value release of its industrialization pipeline, fully preparing for the upcoming capital market milestone.

Qrigincell Therapeutics is committed to developing therapies with global clinical value.CAR-TCell therapy, and has achieved confirmatory proof-of-concept in multiple pipelines (POC) Clinical data. Relying on the company's self-innovatedOri®AbAntibody Screening and Engineering Platform,Ori®ArmoringStructural Enhancement Platform andOnGo(Fast) CMCRapid process expertise successfully built a differentiated product pipeline.

The company's core products includeOri-C101, a targetedGPC3, for the treatment of advanced hepatocellular carcinoma (HCC) AutologousCAR-TDrug. The product has completed investigator-initiated clinical trials. (IIT) And Registered ClinicalIThe phase trial is about to launch a pivotal clinical trial. The clinical data already read out has demonstrated excellent efficacy and safety characteristics, with related achievements being presented multiple times at...ASCOPublished in international top-tier academic conferences. With the current positive clinical progress,Ori-C101Expected to become the world's first approved drug for hepatocellular carcinomaCAR-TMedicine.

In addition to its core pipeline, Qrigincell Therapeutics' full-platform technology system is continuously incubating multiple next-generation multi-target, multi-mechanismCAR-TProducts, including secretory type, rapid production type, and multiple modelsin vivo CAR-TProject.

It is worth mentioning that, in January 202612Day,QrigincellTherapeutics（Oricell) Announced Completion7000Million USDC1Round of financing.

Dr. Yang Huanfeng, Chairman and CEO of Qrigincell Therapeutics, stated:“Qrigincell Therapeutics will continue to focus on the global clinical advancement of its core pipeline, deepeningin vivo CAR-TAnd Solid TumorsCAR-TThe development of revolutionary technologies fully utilizes the company's multiple advantages in technical accumulation, policy environment, and market demand, accelerating the development speed of clinical-stage products, reducing costs, and increasing accessibility. Our goal is to bring new hope of cure to cancer patients worldwide with more breakthrough cell therapy solutions, steadily advancing towards becoming a global leader in immunotherapy.”